Agios Pharmaceuticals AGIO Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Agios Pharmaceuticals (AGIO) reported cash, cash equivalents, and marketable securities of $461.4M in Q1 2026.
- How has Agios Pharmaceuticals's cash, cash equivalents, and marketable securities changed year-over-year?
- Agios Pharmaceuticals's cash, cash equivalents, and marketable securities decreased by 21.4% year-over-year, from $586.9M to $461.4M.
- What is the long-term trend for Agios Pharmaceuticals's cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's cash, cash equivalents, and marketable securities has grown at a -14.6% compound annual growth rate (CAGR), from $299M to $136.2M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.